Ardelyx (ARDX) Capital Expenditures Growth (3y) (2016 - 2026)
Ardelyx (ARDX) Capital Expenditures Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 16.27% |
| 10 | Ardelyx | 1.26 Bn | 1.03 Bn | 89.66 Mn | 70.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.18% |
| Dec 31, 2025 | 87.23% |
| Dec 31, 2024 | 102.00% |
| Sep 30, 2024 | -32.48% |
| Jun 30, 2024 | -43.83% |
| Mar 31, 2024 | -42.23% |
| Dec 31, 2023 | -44.39% |
| Sep 30, 2023 | 58.20% |
| Mar 31, 2023 | -17.57% |
| Dec 31, 2021 | -32.59% |
| Sep 30, 2021 | 153.83% |
| Mar 31, 2021 | 141.85% |
| Dec 31, 2020 | 28.26% |
| Sep 30, 2020 | -51.14% |
| Mar 31, 2020 | -71.83% |
| Sep 30, 2019 | -58.65% |
| Jun 30, 2019 | -46.18% |
| Mar 31, 2019 | -6.21% |
| Dec 31, 2018 | -14.18% |
| Sep 30, 2018 | -26.22% |